Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Pacira Pharma (PCRX) Misses Q4 EPS by 3c
February 28, 2023 8:13 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.80, $0.03 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $172 million versus the consensus estimate of $178.59 million.
Today the company is providing full-year 2023 financial guidance as follows:
EXPAREL net product... More